See more : New Constructor’s Network Co., Ltd. (7057.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bloomage BioTechnology Corporation Limited (688363.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bloomage BioTechnology Corporation Limited, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- 88 Energy Limited (88E.L) Income Statement Analysis – Financial Results
- Pioneer Motor Public Company Limited (PIMO.BK) Income Statement Analysis – Financial Results
- Enma Al Rawabi Investment & Real Estate Development Company (9521.SR) Income Statement Analysis – Financial Results
- Fidelity China Special Situations PLC (FECHF) Income Statement Analysis – Financial Results
- Rugvista Group AB (publ) (RUG.ST) Income Statement Analysis – Financial Results
Bloomage BioTechnology Corporation Limited (688363.SS)
About Bloomage BioTechnology Corporation Limited
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is headquartered in Jinan, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.08B | 6.36B | 4.95B | 2.63B | 1.89B | 1.26B | 818.05M | 733.12M | 650.87M | 481.30M | 375.18M | 274.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.62B | 1.46B | 1.09B | 489.47M | 383.57M | 253.58M | 200.59M | 165.97M | 173.19M | 105.90M | 75.32M | 84.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.45B | 4.90B | 3.86B | 2.14B | 1.50B | 1.01B | 617.46M | 567.15M | 477.68M | 375.40M | 299.86M | 190.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 73.32% | 76.99% | 78.07% | 81.41% | 79.66% | 79.92% | 75.48% | 77.36% | 73.39% | 78.00% | 79.92% | 69.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 446.35M | 388.19M | 284.34M | 141.16M | 93.89M | 52.87M | 25.72M | 23.96M | 29.80M | 15.66M | 15.15M | 9.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 138.96M | 127.85M | 97.07M | 38.89M | 42.62M | 54.22M | 175.05M | 110.07M | 141.91M | 104.13M | 116.11M | 44.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.84B | 3.05B | 2.44B | 1.10B | 521.37M | 283.75M | 125.47M | 107.00M | 107.07M | 74.65M | 58.62M | 33.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.98B | 3.18B | 2.53B | 1.14B | 563.99M | 337.97M | 300.52M | 217.08M | 209.62M | 178.77M | 174.73M | 77.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 318.82M | 220.03M | 130.52M | 104.17M | 142.78M | -9.47M | -15.46M | 17.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.75B | 3.79B | 2.95B | 1.38B | 800.65M | 518.00M | 333.35M | 256.16M | 239.42M | 173.79M | 168.33M | 73.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost & Expenses | 5.37B | 5.25B | 4.03B | 1.87B | 1.18B | 771.58M | 533.94M | 422.13M | 412.61M | 279.69M | 243.65M | 157.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Income | 38.46M | 38.53M | 24.42M | 18.02M | 8.62M | 2.79M | 2.73M | 34.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.74M | 14.52M | 11.08M | 517.07K | 1.63M | 148.49K | 3.08M | 216.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 292.39M | 228.65M | 161.29M | 75.02M | 62.93M | 48.11M | 43.61M | 35.21M | 40.25M | 14.11M | 12.76M | 10.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 1.01B | 1.38B | 1.06B | 840.40M | 766.33M | 564.04M | 331.10M | 365.52M | 287.19M | 215.72M | 144.29M | 122.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 16.58% | 22.00% | 21.94% | 32.91% | 41.25% | 44.55% | 40.29% | 50.82% | 42.79% | 44.82% | 38.46% | 46.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 708.39M | 1.14B | 905.55M | 757.05M | 699.58M | 524.45M | 284.30M | 320.46M | 238.26M | 201.61M | 131.53M | 117.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income Ratio | 11.66% | 17.87% | 18.30% | 28.76% | 37.10% | 41.52% | 34.75% | 43.71% | 36.61% | 41.89% | 35.06% | 42.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.66M | -201.77K | -15.35M | 1.85M | 1.76M | -9.47M | -235.07K | 9.46M | -359.00K | -2.49M | -5.38M | -5.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 701.72M | 1.14B | 890.20M | 758.90M | 701.09M | 514.98M | 284.06M | 329.92M | 237.90M | 198.12M | 125.76M | 111.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 11.55% | 17.87% | 17.99% | 28.83% | 37.18% | 40.77% | 34.72% | 45.00% | 36.55% | 41.16% | 33.52% | 40.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 118.98M | 174.73M | 114.64M | 113.89M | 116.48M | 91.12M | 61.79M | 60.49M | 47.53M | 36.06M | 31.36M | 22.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 592.56M | 970.92M | 782.33M | 645.84M | 585.61M | 423.86M | 222.27M | 269.43M | 190.39M | 162.07M | 94.40M | 89.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Ratio | 9.75% | 15.27% | 15.81% | 24.53% | 31.06% | 33.56% | 27.17% | 36.75% | 29.25% | 33.67% | 25.16% | 32.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.23 | 2.02 | 1.63 | 1.35 | 1.22 | 0.98 | 2.50 | 0.60 | 0.57 | 0.49 | 0.29 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 1.23 | 2.02 | 1.62 | 1.35 | 1.22 | 0.97 | 2.50 | 0.60 | 0.55 | 0.47 | 0.28 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 481.75M | 480.65M | 480.00M | 480.00M | 480.00M | 430.44M | 361.98M | 361.98M | 336.91M | 332.17M | 321.03M | 312.00M | 312.00M | 312.00M | 312.00M | 312.00M | 312.39M | 311.79M | 316.62M |
| Weighted Avg Shares Out (Dil) | 481.75M | 481.09M | 482.92M | 480.00M | 480.00M | 437.02M | 367.69M | 367.69M | 344.44M | 342.51M | 334.93M | 313.84M | 312.00M | 312.00M | 312.00M | 312.00M | 312.39M | 311.79M | 316.62M |
Source: https://incomestatements.info
Category: Stock Reports